Vol.

41

No.

33

September 11, 2015Sep 11, 2015

Free

DOWNLOAD THE PDF

Cover Story

What's in a Suffix? FDA's Dilemma: How to Name Biologics

By Paul Goldberg

After a courtroom victory against Amgen Inc. this summer, the last of the obstacles was removed for the first biosimilar agent—a white blood cell growth factor—to enter the U.S. market.

HRSA Publishes Long-Awaited 340B Mega-Rule

By Matthew Bin Han Ong

GAO to Investigate Power Morcellation Harms

By Matthew Bin Han Ong

Free Obituary

Gianni Bonadonna, 81, Pioneering Cancer Researcher

CVS Marks First Anniversary Of Stopping Tobacco Sales

70th Annual Lasker Awards Go To Witkin, Elledge, Allison, Medecins Sans Frontieres

Recent Issues

Volume 51 | Issue 43 - November 21, 2025

Scroll to top

What's in a Suffix? FDA's Dilemma: How to Name Biologics

HRSA Publishes Long-Awaited 340B Mega-Rule

GAO to Investigate Power Morcellation Harms

Gianni Bonadonna, 81, Pioneering Cancer Researcher

CVS Marks First Anniversary Of Stopping Tobacco Sales

70th Annual Lasker Awards Go To Witkin, Elledge, Allison, Medecins Sans Frontieres

In Brief

Chad Mirkin Awarded Sackler Prize from National Academy of Sciences

Arteaga and Alt awarded scientific prize by the American-Italian Cancer Foundation

Herbert Fritsche receives award from International Society of Oncology and Biomarkers

Trovagene launches European Trovagene Research Institute

Drugs & Targets

FDA Grants Priority Review to Alectinib in Lung Cancer

Janssen and Alligator Bioscience enter agreement

Sequenom to collaborate with UC San Diego

Vaccinogen enters agreement with Dublin City University over DiCAST

OICR and Structural Genomics Consortium make drug prototype available to the research community

PhRMA publishes report on U.S. drugs in development

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login